146 results on '"Patel, Bhavisha"'
Search Results
2. Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations
3. Spectrum of clonal hematopoiesis in VEXAS syndrome
4. Differential diagnosis of bone marrow failure syndromes guided by machine learning
5. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis
6. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study
7. Efficacy of JAK1/2 inhibition in murine immune bone marrow failure
8. Efficacy of JAK1/2 inhibition in murine immune bone marrow failure
9. Differential diagnosis of bone marrow failure syndromes guided by machine learning
10. Granulocyte Transfusions As an Adjunctive Therapy in Severe Aplastic Anemia
11. Clonal Hematopoiesis in a Broad Age Spectrum of Systemic Vasculitis
12. Eosinophilia in Vexas Syndrome: Expanding Hematologic Phenotype
13. DNMT3A/TET2 Mutant Clonal Hematopoiesis in Vexas Syndrome Results in DNA Hypomethylation and Transcriptional Activation of WT1 and MPL Oncogenic Pathways
14. The Role of Heterozygous Variants in SAMD9/9L and Recessive Bone Marrow Failure-Related Genes in Adults with Severe Aplastic Anemia
15. Characterizing Immunodeficiency in Patients with Telomere Biology Disorders
16. Clonal Hematopoiesis in Vexas Syndrome
17. Thrombotic Manifestations in Patients with Vexas Syndrome
18. JAK 1/2 Inhibition Preserves Hematopoietic Progenitor and Stem Cells, Prevents Aplasia, Inhibits Pro-Inflammatory Cytokines, and Prolongs Survival in Murine Immune Bone Marrow Failure
19. Alemtuzumab and Eltrombopag Combination for Patients with Refractory or Relapsed Severe Aplastic Anemia
20. Predictors, Risk Factors and Outcomes of Patients with SAA with Anti-HLA Class I Antibodies Treated with Immunosuppressive Therapy
21. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study
22. HLA associations, somatic loss of HLA expression, and clinical outcomes in immune aplastic anemia
23. Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study
24. Genomic-Based Machine Learning Towards Prediction of the Etiology of Bone Marrow Failure Syndromes
25. Sars-Cov-2 Infection Associated with Aplastic Anemia and Pure Red Cell Aplasia
26. Clonal Hematopoiesis in Telomere Biology Disorders Associates with the Underlying Germline Defect and Somatic Mutations in POT1, PPM1D, andTERT promoter
27. Strong Predictors of Chromosomal Aberrations and Myeloid Neoplasia Following Immunosuppression Therapy for Severe Aplastic Anemia: A Retrospective Cohort Study
28. U2AF1 and Other Splicing Factor Gene Mutations in Telomere Biology Disorders Are Associated with Hematologic Neoplasia and Worse Overall Survival
29. Early Initiation of Oral Therapy with Cyclosporine and Eltrombopag for Treatment Naïve Severe Aplastic Anemia: Interim Results of a Phase II Trial
30. Distinct Immune and Molecular Profiles of Hepatitis-Associated Aplastic Anemia
31. Clinical Manifestations Are Evolving and Progressive in Patients with Vexas Syndrome
32. Clonal Bone Marrow Plasma Cells Are Common in Patients with Vexas Syndrome
33. Characterization of Hematopoietic Stem and Progenitor Cells of PNH Patients Using Single-Cell RNA Sequencing Analysis
34. VEXAS Syndrome
35. Long-Term Eltrombopag for Bone Marrow Failure Depletes Total Body Iron
36. Myelodysplasia and Bone Marrow Manifestations of Somatic UBA1 Mutated Autoinflammatory Disease
37. Clinical Utility of Plasma Cell-Free DNA for Detection and Quantification of Clonal Hematopoiesis
38. Somatic Mutations in a Single Residue of UBA1 Cause Vexas, a Severe Adult-Onset Rheumatic Disease Associated with Myeloid Dysplasia
39. Outcomes in Pediatric Patients with Severe Aplastic Anemia Treated with Standard Immunosuppression and Eltrombopag
40. Deficit of Circulating CD19+CD24hiCD38hi Regulatory B Cells in Severe Aplastic Anemia
41. Spectrum and Clinical Significance of HLA Class I Alleles and Their Somatic Mutations in Immune Aplastic Anemia
42. Ruxolitinib is more effective than other JAK Inhibitors to treat VEXAS Syndrome: a retrospective multi center study
43. Ahemolytic PNH: Clinical Features of a Distinct Phenotype of Paroxysmal Nocturnal Hemoglobinuria
44. Applicability of the Chronic Lymphocytic Leukemia (CLL)-IPI on Patients Treated with Front-Line Ibrutinib in the Real World: The Case for New Prognostic Models
45. DNMT3A/TET2Mutant Clonal Hematopoiesis in Vexas Syndrome Results in DNA Hypomethylation and Transcriptional Activation of WT1and MPLOncogenic Pathways
46. The Role of Heterozygous Variants in SAMD9/9Land Recessive Bone Marrow Failure-Related Genes in Adults with Severe Aplastic Anemia
47. Hematologic Recovery After Liver Transplantation
48. Myelodysplasia and Bone Marrow Manifestations of Somatic UBA1Mutated Autoinflammatory Disease
49. Somatic Mutations in a Single Residue of UBA1Cause Vexas, a Severe Adult-Onset Rheumatic Disease Associated with Myeloid Dysplasia
50. Clonal Hematopoiesis in Telomere Biology Disorders Associates with the Underlying Germline Defect and Somatic Mutations in POT1, PPM1D,and TERTpromoter
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.